pharmaceuticals, evolution
Who Sleeps?
Who Sleeps?
The Scientist Staff, Jerome Siegel | Mar 1, 2016
Once believed to be unique to birds and mammals, sleep is found across the metazoan kingdom. Some animals, it seems, can’t live without it, though no one knows exactly why.
Week in Review: February 22–26
Week in Review: February 22–26
Jef Akst | Feb 26, 2016
Questions about how E. coli evolves; spermatids in a dish; fighting bacteria with virus-like molecule; what drives metastasis; antibodies fight Ebola in monkeys
Similar Data, Different Conclusions
Similar Data, Different Conclusions
Ashley P. Taylor | Feb 23, 2016
By tweaking certain conditions of a long-running experiment on E. coli, scientists found that some bacteria could be prompted to express a mutant phenotype sooner, without the “generation of new genetic information.” The resulting debate—whether the data support evolutionary theory—is more about semantics than science.
Abbott Acquires Diagnostics Firm
Abbott Acquires Diagnostics Firm
Kerry Grens | Feb 2, 2016
In a deal worth $5.8 billion, Abbott Laboratories is buying medical test–maker Alere.
Chat With Charlie
Chat With Charlie
The Scientist Staff | Feb 1, 2016
See a preview of the app that lets you ask questions of a virtual Charles Darwin.
Fighting Back
Fighting Back
Mary Beth Aberlin | Feb 1, 2016
Plants can’t run away from attackers, so they’ve evolved unique immune defenses to protect themselves.
iDarwin
iDarwin
Jef Akst | Feb 1, 2016
A synthetic interview with the father of evolutionary theory, now available as a smartphone app, teaches students and the public about the famed biologist.
Jason Holliday: Tree Tracker
Jason Holliday: Tree Tracker
Jef Akst | Feb 1, 2016
Associate Professor, Virginia Tech, Department of Forest Resources and Environmental Conservation. Age: 37
Lizard Secretes Heat
Lizard Secretes Heat
Bob Grant | Jan 25, 2016
Researchers confirm the unprecedented endothermic abilities of a South American reptile.
Shire to Buy Baxalta for $32 Billion
Shire to Buy Baxalta for $32 Billion
Tracy Vence | Jan 12, 2016
The Dublin-based pharma giant is set to acquire Baxalta, an Illinois-based Baxter spinoff, expanding its rare disease drug portfolio.